Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer

PURPOSE: To gain a greater understanding of the potential of the Aurora kinase A inhibitor MLN8237 in the treatment of pediatric malignancies. METHODS: The activity of MLN8237 was evaluated against 28 neuroblastoma and Ewing sarcoma cell lines, and its in vivo efficacy was studied over a range of do...

Descripción completa

Detalles Bibliográficos
Autores principales: Carol, Hernan, Boehm, Ingrid, Reynolds, C. Patrick, Kang, Min H., Maris, John M., Morton, Christopher L., Gorlick, Richard, Kolb, E. Anders, Keir, Stephen T., Wu, Jianrong, Wozniak, Amy E., Yang, Yu, Manfredi, Mark, Ecsedy, Jeffrey, Wang, Jianmin, Neale, Geoffrey, Houghton, Peter J., Smith, Malcolm A., Lock, Richard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215888/
https://www.ncbi.nlm.nih.gov/pubmed/21448591
http://dx.doi.org/10.1007/s00280-011-1618-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215888/
https://www.ncbi.nlm.nih.gov/pubmed/21448591
http://dx.doi.org/10.1007/s00280-011-1618-8

Ejemplares similares